ProfileGDS5678 / 1459888_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 77% 79% 79% 77% 65% 68% 73% 70% 79% 81% 81% 80% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0521276
GSM967853U87-EV human glioblastoma xenograft - Control 25.2065877
GSM967854U87-EV human glioblastoma xenograft - Control 35.4543779
GSM967855U87-EV human glioblastoma xenograft - Control 45.714779
GSM967856U87-EV human glioblastoma xenograft - Control 55.2217177
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9747365
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2017168
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6596673
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3468870
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5144679
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8139881
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8472581
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6092780
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.806581